Share on StockTwits

Prothena Co. PLC (NASDAQ:PRTA) has received a consensus recommendation of “Buy” from the eight analysts that are currently covering the stock, AnalystRatings.NET reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $41.92.

Several analysts have recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of Prothena Co. PLC in a research note on Thursday. They set an “outperform” rating and a $40.00 price target on the stock. Separately, analysts at Ladenburg Thalmann initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, May 22nd. They set a “buy” rating and a $36.50 price target on the stock. Finally, analysts at Wedbush upgraded shares of Prothena Co. PLC to a “best ideas list” rating in a research note on Friday, April 25th.

Shares of Prothena Co. PLC (NASDAQ:PRTA) traded down 0.45% on Friday, hitting $20.845. 68,637 shares of the company’s stock traded hands. Prothena Co. PLC has a 52 week low of $13.34 and a 52 week high of $49.24. The stock’s 50-day moving average is $22.03 and its 200-day moving average is $28.17. The company’s market cap is $456.6 million. Prothena Co. PLC also saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,326,281 shares, a growth of 114.5% from the June 13th total of 618,347 shares. Approximately 5.0% of the shares of the company are sold short. Based on an average daily volume of 691,079 shares, the days-to-cover ratio is currently 1.9 days.

Prothena Co. PLC (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.81 by $0.03.

Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.